Cargando…
Case Report: Clinical Experience With Avelumab in Patients With Metastatic Merkel Cell Carcinoma and Brain Metastases Treated in Europe
Merkel cell carcinoma (MCC) is a rare and aggressive skin cancer that can metastasize rapidly. In patients with metastatic MCC (mMCC), brain metastases are uncommon but are associated with poor prognosis; furthermore, there is limited published literature regarding treatment of these patients, and n...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8194357/ https://www.ncbi.nlm.nih.gov/pubmed/34123840 http://dx.doi.org/10.3389/fonc.2021.672021 |
_version_ | 1783706403017326592 |
---|---|
author | Fife, Kate Tétu, Pauline Prabhakaran, Jessica Lebbé, Celeste Grignani, Giovanni |
author_facet | Fife, Kate Tétu, Pauline Prabhakaran, Jessica Lebbé, Celeste Grignani, Giovanni |
author_sort | Fife, Kate |
collection | PubMed |
description | Merkel cell carcinoma (MCC) is a rare and aggressive skin cancer that can metastasize rapidly. In patients with metastatic MCC (mMCC), brain metastases are uncommon but are associated with poor prognosis; furthermore, there is limited published literature regarding treatment of these patients, and no specific regimens are currently recommended by guidelines. Avelumab, an anti–programmed death ligand 1 monoclonal antibody, was the first approved treatment for patients with mMCC. Here, we present 4 cases of patients with mMCC and brain metastases treated with avelumab. Patient age ranged from 48 to 70 years, and all patients received avelumab as second-line therapy following disease progression with platinum-based chemotherapy. Patient cases 1 and 2 received avelumab alone and experienced rapid disease progression according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1). In patient case 3, avelumab alone resulted in a prolonged complete response by RECIST 1.1 of 1 brain metastasis and partial response by RECIST 1.1 of a second brain metastasis. After 11 months of avelumab treatment, the patient received concurrent stereotactic radiosurgery that resulted in complete response of the second metastasis. Patient case 4 achieved a partial response by RECIST 1.1 with avelumab plus stereotactic radiosurgery. These results suggest that avelumab followed by radiotherapy or with concurrent radiotherapy may be an effective treatment option for patients with mMCC and brain metastases. |
format | Online Article Text |
id | pubmed-8194357 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-81943572021-06-12 Case Report: Clinical Experience With Avelumab in Patients With Metastatic Merkel Cell Carcinoma and Brain Metastases Treated in Europe Fife, Kate Tétu, Pauline Prabhakaran, Jessica Lebbé, Celeste Grignani, Giovanni Front Oncol Oncology Merkel cell carcinoma (MCC) is a rare and aggressive skin cancer that can metastasize rapidly. In patients with metastatic MCC (mMCC), brain metastases are uncommon but are associated with poor prognosis; furthermore, there is limited published literature regarding treatment of these patients, and no specific regimens are currently recommended by guidelines. Avelumab, an anti–programmed death ligand 1 monoclonal antibody, was the first approved treatment for patients with mMCC. Here, we present 4 cases of patients with mMCC and brain metastases treated with avelumab. Patient age ranged from 48 to 70 years, and all patients received avelumab as second-line therapy following disease progression with platinum-based chemotherapy. Patient cases 1 and 2 received avelumab alone and experienced rapid disease progression according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1). In patient case 3, avelumab alone resulted in a prolonged complete response by RECIST 1.1 of 1 brain metastasis and partial response by RECIST 1.1 of a second brain metastasis. After 11 months of avelumab treatment, the patient received concurrent stereotactic radiosurgery that resulted in complete response of the second metastasis. Patient case 4 achieved a partial response by RECIST 1.1 with avelumab plus stereotactic radiosurgery. These results suggest that avelumab followed by radiotherapy or with concurrent radiotherapy may be an effective treatment option for patients with mMCC and brain metastases. Frontiers Media S.A. 2021-05-28 /pmc/articles/PMC8194357/ /pubmed/34123840 http://dx.doi.org/10.3389/fonc.2021.672021 Text en Copyright © 2021 Fife, Tétu, Prabhakaran, Lebbé and Grignani https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Fife, Kate Tétu, Pauline Prabhakaran, Jessica Lebbé, Celeste Grignani, Giovanni Case Report: Clinical Experience With Avelumab in Patients With Metastatic Merkel Cell Carcinoma and Brain Metastases Treated in Europe |
title | Case Report: Clinical Experience With Avelumab in Patients With Metastatic Merkel Cell Carcinoma and Brain Metastases Treated in Europe |
title_full | Case Report: Clinical Experience With Avelumab in Patients With Metastatic Merkel Cell Carcinoma and Brain Metastases Treated in Europe |
title_fullStr | Case Report: Clinical Experience With Avelumab in Patients With Metastatic Merkel Cell Carcinoma and Brain Metastases Treated in Europe |
title_full_unstemmed | Case Report: Clinical Experience With Avelumab in Patients With Metastatic Merkel Cell Carcinoma and Brain Metastases Treated in Europe |
title_short | Case Report: Clinical Experience With Avelumab in Patients With Metastatic Merkel Cell Carcinoma and Brain Metastases Treated in Europe |
title_sort | case report: clinical experience with avelumab in patients with metastatic merkel cell carcinoma and brain metastases treated in europe |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8194357/ https://www.ncbi.nlm.nih.gov/pubmed/34123840 http://dx.doi.org/10.3389/fonc.2021.672021 |
work_keys_str_mv | AT fifekate casereportclinicalexperiencewithavelumabinpatientswithmetastaticmerkelcellcarcinomaandbrainmetastasestreatedineurope AT tetupauline casereportclinicalexperiencewithavelumabinpatientswithmetastaticmerkelcellcarcinomaandbrainmetastasestreatedineurope AT prabhakaranjessica casereportclinicalexperiencewithavelumabinpatientswithmetastaticmerkelcellcarcinomaandbrainmetastasestreatedineurope AT lebbeceleste casereportclinicalexperiencewithavelumabinpatientswithmetastaticmerkelcellcarcinomaandbrainmetastasestreatedineurope AT grignanigiovanni casereportclinicalexperiencewithavelumabinpatientswithmetastaticmerkelcellcarcinomaandbrainmetastasestreatedineurope |